AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR) experienced a notable decline in short interest during January. As of January 31st, the company's short interest stood at 59,500 shares, marking a significant 14.0% drop from the previous total of 69,200 shares reported on January 15th. Currently, around 2.6% of AlloVir's total shares are sold short. Given the average daily trading volume of 26,100 shares, the short-interest ratio is now 2.3 days.

Hedge Funds and Institutional Investment

Recent activity among institutional investors and hedge funds shows a mix of investments in AlloVir. Northern Trust Corp increased its holdings by 0.8% in the last quarter, bringing its total ownership to 159,685 shares valued at approximately $67,000, after buying an extra 1,267 shares. Meanwhile, Jane Street Group LLC notably boosted its stake by 47.8%, now holding 123,159 shares worth around $52,000 after acquiring an additional 39,808 shares during the same timeframe. Raymond James Financial Inc. also entered a new investment in AlloVir valued at about $25,000. Additionally, Gilead Sciences Inc. acquired a stake in AlloVir valued at approximately $6,987,000. Collectively, hedge funds and institutional investors own about 66.05% of the company's stock.

Current Stock Performance

As of the latest analysis, ALVR shares opened at $9.90. The company holds a market capitalization of $49.80 million, with a price-to-earnings ratio of -0.49 and a beta coefficient of 0.65. The fifty-day simple moving average is positioned at $10.10, while the 200-day average is $14.58. Over the past year, AlloVir's stock has seen a low of $7.96 and a high of $24.15.

About AlloVir

AlloVir, Inc. is committed to researching, developing, and commercializing innovative off-the-shelf VST therapies aimed at preventing and treating severe viral-related diseases. Specifically, the company focuses on creating novel cell therapies to help restore natural immunity in patients suffering from life-threatening virus-associated diseases, particularly those with severely compromised immune systems.

Further Reading

Investors interested in the biotechnology sector may find additional resources and analyses helpful in navigating market opportunities.

AlloVir, Short, Investment